Urovant Sciences Ltd.
CIK 0001740547
Revenue (TTM)
—
Q3 Feb 2021
Net Income (TTM)
−$153.71M
−31.8% YoY
Q3 Feb 2021
EPS Diluted (TTM)
—
Q3 Feb 2021
Gross Margin
—
Q3 Feb 2021
Operating Margin
—
Q3 Feb 2021
Net Margin
—
Q3 Feb 2021
Free Cash Flow (TTM)
—
Q3 Feb 2021
Cash
$71.3M
Q3 Feb 2021
Total Debt
$253.05M
Q3 Feb 2021
Shares Outstanding
32.74M sh
Q3 Feb 2021
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.